Clasp Therapeutics是一家总部位于美国马萨诸塞州的生物技术公司，致力于开发针对每位患者免疫系统的模块化T细胞诱导体（TCE），这些TCE针对常见的 ...

CLASP edge distribution was non-uniform, forming distinct domains that were persistent over tens of minutes, yet exhibited rapid turnover of CLASP molecules, as evidenced by GFP–CLASP's ...

About Clasp Therapeutics, Inc. Clasp is pioneering precision in immuno-oncology through next-generation T cell engagers (TCEs) that target tumor-specific oncogenic driver mutations common across ...

Clasp’s platform identifies mutation-associated neoantigens and develops TCEs that can selectively bind HLA (human leukocyte antigen)-presented peptides derived from these oncogenic drivers.

Clasp Therapeutics, a company that aims to create a next-generation version of immunoncology drugs called bispecific T cell engagers (TCEs), launched today with $150 million in series A financing.